{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T04:37:18Z","timestamp":1795063038140,"version":"4.10.2"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["HG010615"],"award-info":[{"award-number":["HG010615"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030_189147"],"award-info":[{"award-number":["310030_189147"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Electronic health records (EHRs) coupled with large-scale biobanks offer great promises to unravel the genetic underpinnings of treatment efficacy. However, medication-induced biomarker trajectories stemming from such records remain poorly studied. Here, we extract clinical and medication prescription data from EHRs and conduct GWAS and rare variant burden tests in the UK Biobank (discovery) and the All of Us program (replication) on ten cardiometabolic drug response outcomes including lipid response to statins, HbA1c response to metformin and blood pressure response to antihypertensives (N = 932-28,880). Our discovery analyses in participants of European ancestry recover previously reported pharmacogenetic signals at genome-wide significance level (\n                    <jats:italic>APOE<\/jats:italic>\n                    ,\n                    <jats:italic>LPA<\/jats:italic>\n                    and\n                    <jats:italic>SLCO1B1<\/jats:italic>\n                    ) and a novel rare variant association in\n                    <jats:italic>GIMAP5<\/jats:italic>\n                    with HbA1c response to metformin. Importantly, these associations are treatment-specific and not associated with biomarker progression in medication-naive individuals. We also found polygenic risk scores to predict drug response, though they explained less than 2% of the variance. In summary, we present an EHR-based framework to study the genetics of drug response and systematically investigated the common and rare pharmacogenetic contribution to cardiometabolic drug response phenotypes in 41,732 UK Biobank and 14,277 All of Us participants.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-58152-3","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T21:15:38Z","timestamp":1742937338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Leveraging large-scale biobank EHRs to enhance pharmacogenetics of cardiometabolic disease medications"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2599-9207","authenticated-orcid":false,"given":"Marie C.","family":"Sadler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1159-5652","authenticated-orcid":false,"given":"Alexander","family":"Apostolov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6708-091X","authenticated-orcid":false,"given":"Caterina","family":"Cevallos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3613-8450","authenticated-orcid":false,"given":"Chiara","family":"Auwerx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0482-7342","authenticated-orcid":false,"given":"Diogo M.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3859-2905","authenticated-orcid":false,"given":"Russ B.","family":"Altman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8285-7523","authenticated-orcid":false,"given":"Zolt\u00e1n","family":"Kutalik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"58152_CR1","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/cpt.2349","volume":"110","author":"G McInnes","year":"2021","unstructured":"McInnes, G., Yee, SookWah, Pershad, Y. & Altman, R. B. Genomewide association studies in pharmacogenomics. Clin. Pharmacol. Therapeutics 110, 637\u2013648 (2021).","journal-title":"Clin. Pharmacol. Therapeutics"},{"key":"58152_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrg.2016.12","volume":"17","author":"MR Nelson","year":"2016","unstructured":"Nelson, M. R. et al. The genetics of drug efficacy: opportunities and challenges. Nat. Rev. Genet. 17, 197\u2013206 (2016).","journal-title":"Nat. Rev. Genet."},{"key":"58152_CR3","doi-asserted-by":"crossref","unstructured":"Pirmohamed, M. Pharmacogenomics: current status and future perspectives. Nat. Rev. Genet. 24, 350\u2013362 (2023).","DOI":"10.1038\/s41576-022-00572-8"},{"key":"58152_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6068","volume":"5","author":"I Postmus","year":"2014","unstructured":"Postmus, I. et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat. Commun. 5, 5068 (2014).","journal-title":"Nat. Commun."},{"key":"58152_CR5","first-page":"e002043","volume":"11","author":"A Oni-Orisan","year":"2018","unstructured":"Oni-Orisan, A. et al. Characterization of statin low-density lipoprotein cholesterol dose-response using electronic health records in a large population-based cohort. Circulation: Genom. Precis. Med. 11, e002043 (2018).","journal-title":"Circulation: Genom. Precis. Med."},{"key":"58152_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-019-0109-4","volume":"5","author":"A Oni-Orisan","year":"2020","unstructured":"Oni-Orisan, A. et al. The impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quantitative change. NPJ Genom. Med. 5, 1 (2020).","journal-title":"NPJ Genom. Med."},{"key":"58152_CR7","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/ng.3632","volume":"48","author":"K Zhou","year":"2016","unstructured":"Zhou, K. et al. Variation in the glucose transporter gene slc2a2 is associated with glycemic response to metformin. Nat. Genet. 48, 1055\u20131059 (2016).","journal-title":"Nat. Genet."},{"key":"58152_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S2213-8587(22)00340-0","volume":"11","author":"AY Dawed","year":"2023","unstructured":"Dawed, A. Y. et al. Pharmacogenomics of glp-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. Lancet Diab. Endocrinol. 11, 33\u201341 (2023).","journal-title":"Lancet Diab. Endocrinol."},{"key":"58152_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.116.08267","volume":"69","author":"E Salvi","year":"2017","unstructured":"Salvi, E. et al. Genome-wide and gene-based meta-analyses identify novel loci influencing blood pressure response to hydrochlorothiazide. Hypertension 69, 51\u201359 (2017).","journal-title":"Hypertension"},{"key":"58152_CR10","doi-asserted-by":"publisher","first-page":"e013115","DOI":"10.1161\/JAHA.119.013115","volume":"8","author":"S Singh","year":"2019","unstructured":"Singh, S. et al. Genome-wide meta-analysis of blood pressure response to \u03b21-blockers: results from icaps (international consortium of antihypertensive pharmacogenomics studies). J. Am. Heart Assoc. 8, e013115 (2019).","journal-title":"J. Am. Heart Assoc."},{"key":"58152_CR11","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/cpt.2355","volume":"110","author":"CW McDonough","year":"2021","unstructured":"McDonough, C. W. et al. Adverse cardiovascular outcomes and antihypertensive treatment: A genome-wide interaction meta-analysis in the international consortium for antihypertensive pharmacogenomics studies. Clin. Pharmacol. Therapeutics 110, 723\u2013732 (2021).","journal-title":"Clin. Pharmacol. Therapeutics"},{"key":"58152_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/cpt.350","volume":"100","author":"WS Bush","year":"2016","unstructured":"Bush, W. S. et al. Genetic variation among 82 pharmacogenes: the PGRNseq data from the eMERGE network. Clin. Pharmacol. Therapeutics 100, 160\u2013169 (2016).","journal-title":"Clin. Pharmacol. Therapeutics"},{"key":"58152_CR13","doi-asserted-by":"crossref","unstructured":"Auwerx, C., Sadler, M. C., Reymond, A. & Kutalik, Z. From pharmacogenetics to pharmaco-omics: Milestones and future directions. Hum. Genet. Genomics Adv. 3, 100100 (2022).","DOI":"10.1016\/j.xhgg.2022.100100"},{"key":"58152_CR14","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41431-018-0300-6","volume":"27","author":"T Tasa","year":"2019","unstructured":"Tasa, T. et al. Genetic variation in the Estonian population: pharmacogenomics study of adverse drug effects using electronic health records. Eur. J. Hum. Genet. 27, 442\u2013454 (2019).","journal-title":"Eur. J. Hum. Genet."},{"key":"58152_CR15","doi-asserted-by":"crossref","unstructured":"McInnes, G. & Altman, R. B. Drug response pharmacogenetics for 200,000 UK biobank participants. In BIOCOMPUTING 2021: Proc. Pacific Symposium (eds Altman, R. B. et al.) 184\u2013195 (World Scientific, 2020).","DOI":"10.1142\/9789811232701_0018"},{"key":"58152_CR16","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/cpt.2352","volume":"110","author":"MustafaAdnan Malki","year":"2021","unstructured":"Malki, M. A., Dawed, A. Y., Hayward, C., Doney, A. & Pearson, E. R. Utilizing large electronic medical record data sets to identify novel drug\u2013gene interactions for commonly used drugs. Clin. Pharmacol. Therapeutics 110, 816\u2013825 (2021).","journal-title":"Clin. Pharmacol. Therapeutics"},{"key":"58152_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41591-022-02122-5","volume":"29","author":"T Kiiskinen","year":"2023","unstructured":"Kiiskinen, T. et al. Genetic predictors of lifelong medication-use patterns in cardiometabolic diseases. Nat. Med. 29, 209\u2013218 (2023).","journal-title":"Nat. Med."},{"key":"58152_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","volume":"562","author":"C Bycroft","year":"2018","unstructured":"Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203\u2013209 (2018).","journal-title":"Nature"},{"key":"58152_CR19","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1056\/NEJMsr1809937","volume":"381","author":"The All of Us Research Program Investigators.","year":"2019","unstructured":"The All of Us Research Program Investigators. The \u201cAll of Us\u201d research program. N. Engl. J. Med. 381, 668\u2013676 (2019).","journal-title":"N. Engl. J. Med."},{"key":"58152_CR20","first-page":"257","volume":"5","author":"DI Chasman","year":"2012","unstructured":"Chasman, D. I. et al. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circulation: Cardiovasc. Genet. 5, 257\u2013264 (2012).","journal-title":"Circulation: Cardiovasc. Genet."},{"key":"58152_CR21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/HJH.0b013e3283410390","volume":"29","author":"P Svensson-F\u00e4rbom","year":"2011","unstructured":"Svensson-F\u00e4rbom, P. et al. A functional variant of the nedd4l gene is associated with beneficial treatment response with \u03b2-blockers and diuretics in hypertensive patients. J. Hypertension 29, 388\u2013395 (2011).","journal-title":"J. Hypertension"},{"key":"58152_CR22","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1097\/HJH.0b013e3283536338","volume":"30","author":"V Hamrefors","year":"2012","unstructured":"Hamrefors, V. et al. Pharmacogenetic implications for eight common blood pressure-associated single-nucleotide polymorphisms. J. Hypertension 30, 1151\u20131160 (2012).","journal-title":"J. Hypertension"},{"key":"58152_CR23","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/jmedgenet-2016-103966","volume":"53","author":"I Postmus","year":"2016","unstructured":"Postmus, I. et al. Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. J. Med. Genet. 53, 835\u2013845 (2016).","journal-title":"J. Med. Genet."},{"key":"58152_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/ng.735","volume":"43","author":"LW Harries","year":"2011","unstructured":"Harries, L. W. et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat. Genet. 43, 117\u2013120 (2011).","journal-title":"Nat. Genet."},{"key":"58152_CR25","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.2337\/db17-1164","volume":"67","author":"DM Rotroff","year":"2018","unstructured":"Rotroff, D. M. et al. Genetic variants in CPA6 and PRPF31 are associated with variation in response to metformin in individuals with type 2 diabetes. Diabetes 67, 1428\u20131440 (2018).","journal-title":"Diabetes"},{"key":"58152_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41569-021-00613-5","volume":"19","author":"A Mehta","year":"2022","unstructured":"Mehta, A. & Shapiro, M. D. Apolipoproteins in vascular biology and atherosclerotic disease. Nat. Rev. Cardiol. 19, 168\u2013179 (2022).","journal-title":"Nat. Rev. Cardiol."},{"key":"58152_CR27","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1194\/jlr.P021113","volume":"53","author":"HA Deshmukh","year":"2012","unstructured":"Deshmukh, H. A. et al. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J. lipid Res. 53, 1000\u20131011 (2012).","journal-title":"J. lipid Res."},{"key":"58152_CR28","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s00210-006-0040-y","volume":"372","author":"J K\u00f6nig","year":"2006","unstructured":"K\u00f6nig, J. Seithel, A., Gradhand, U. & Fromm, M. F. Pharmacogenomics of human oatp transporters. Naunyn-Schmiedeberg\u2019s. Arch. Pharmacol. 372, 432\u2013443 (2006).","journal-title":"Naunyn-Schmiedeberg\u2019s. Arch. Pharmacol."},{"key":"58152_CR29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"SEARCH Collaborative Group.","year":"2008","unstructured":"SEARCH Collaborative Group. Slco1b1 variants and statin-induced myopathy\u2014a genomewide study. N. Engl. J. Med. 359, 789\u2013799 (2008).","journal-title":"N. Engl. J. Med."},{"key":"58152_CR30","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/eurheartj\/ehs344","volume":"34","author":"JC Hopewell","year":"2013","unstructured":"Hopewell, J. C. et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the heart protection study. Eur. Heart J. 34, 982\u2013992 (2013).","journal-title":"Eur. Heart J."},{"key":"58152_CR31","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.atherosclerosis.2015.03.025","volume":"240","author":"J Patel","year":"2015","unstructured":"Patel, J., Superko, H. R., Martin, S. S., Blumenthal, R. S. & Christopher-Stine, L. Genetic and immunologic susceptibility to statin-related myopathy. Atherosclerosis 240, 260\u2013271 (2015).","journal-title":"Atherosclerosis"},{"key":"58152_CR32","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1185\/030079903125002225","volume":"19","author":"S Tsiara","year":"2003","unstructured":"Tsiara, S., Elisaf, M. & Mikhailidis, D. P. Early vascular benefits of statin therapy. Curr. Med. Res. Opin. 19, 540\u2013556 (2003).","journal-title":"Curr. Med. Res. Opin."},{"key":"58152_CR33","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1185\/030079906X112750","volume":"22","author":"M Ulcickas Yood","year":"2006","unstructured":"Ulcickas Yood, M., Elston Lafata, J., Koro, C., Wells, K. E. & Pladevall, M. Time to pharmacotherapy change in response to elevated hba1c test results. Curr. Med. Res. Opin. 22, 1567\u20131574 (2006).","journal-title":"Curr. Med. Res. Opin."},{"key":"58152_CR34","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41586-023-06957-x","volume":"627","author":"The All of Us Research Program Genomics Investigators.","year":"2024","unstructured":"The All of Us Research Program Genomics Investigators. Genomic data in the all of us research program. Nature 627, 340\u2013346 (2024).","journal-title":"Nature"},{"key":"58152_CR35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-023-06045-0","volume":"625","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. A genomic mutational constraint map using variation in 76,156 human genomes. Nature 625, 92\u2013100 (2024).","journal-title":"Nature"},{"key":"58152_CR36","doi-asserted-by":"publisher","first-page":"D977","DOI":"10.1093\/nar\/gkac1010","volume":"51","author":"E Sollis","year":"2023","unstructured":"Sollis, E. et al. The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource. Nucleic Acids Res. 51, D977\u2013D985 (2023).","journal-title":"Nucleic Acids Res."},{"key":"58152_CR37","doi-asserted-by":"crossref","unstructured":"Oliveira-Paula, G. H., Pereira, S. C., Tanus-Santos, J. E. & Lacchini, R. Pharmacogenomics and hypertension: current insights. Pharmacogenomics Pers. Med. 12, 341\u2013359 (2020).","DOI":"10.2147\/PGPM.S230201"},{"key":"58152_CR38","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/biostatistics\/kxs014","volume":"13","author":"S Lee","year":"2012","unstructured":"Lee, S., Wu, M. C. & Lin, X. Optimal tests for rare variant effects in sequencing association studies. Biostatistics 13, 762\u2013775 (2012).","journal-title":"Biostatistics"},{"key":"58152_CR39","doi-asserted-by":"publisher","first-page":"5885","DOI":"10.4049\/jimmunol.1500016","volume":"194","author":"MT Heinonen","year":"2015","unstructured":"Heinonen, M. T. et al. Gimap gtpase family genes: potential modifiers in autoimmune diabetes, asthma, and allergy. J. Immunol. 194, 5885\u20135894 (2015).","journal-title":"J. Immunol."},{"key":"58152_CR40","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt.2350","volume":"110","author":"M Whirl-Carrillo","year":"2021","unstructured":"Whirl-Carrillo, M. et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Therapeutics 110, 563\u2013572 (2021).","journal-title":"Clin. Pharmacol. Therapeutics"},{"key":"58152_CR41","doi-asserted-by":"crossref","unstructured":"Zhang, C. et al. Response to anti-IL17 therapy in inflammatory disease is not strongly impacted by genetic background. The Am. J. Hum. Genet. 110, 1817 (2023).","DOI":"10.1016\/j.ajhg.2023.08.010"},{"key":"58152_CR42","doi-asserted-by":"publisher","unstructured":"Cordioli, M. et al. Socio-demographic and genetic risk factors for drug adherence and persistence: a retrospective nationwide and biobank study across 5 medication classes and 1 845 665 individuals. medRxiv https:\/\/doi.org\/10.1101\/2023.10.09.23296740 (2023).","DOI":"10.1101\/2023.10.09.23296740"},{"key":"58152_CR43","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/aje\/kwi187","volume":"162","author":"MM Glymour","year":"2005","unstructured":"Glymour, M. M., Weuve, J., Berkman, L. F., Kawachi, I. & Robins, J. M. When is baseline adjustment useful in analyses of change? an example with education and cognitive change. Am. J. Epidemiol. 162, 267\u2013278 (2005).","journal-title":"Am. J. Epidemiol."},{"key":"58152_CR44","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000181156","volume":"67","author":"PF McArdle","year":"2009","unstructured":"McArdle, P. F. & Whitcomb, B. W. Improper adjustment for baseline in genetic association studies of change in phenotype. Hum. Heredity 67, 176\u2013182 (2009).","journal-title":"Hum. Heredity"},{"key":"58152_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-022-00303-2","volume":"7","author":"H Zhang","year":"2022","unstructured":"Zhang, H., Chhibber, A., Shaw, P. M., Mehrotra, D. V. & Shen, J. A statistical perspective on baseline adjustment in pharmacogenomic genome-wide association studies of quantitative change. NPJ Genom. Med. 7, 33 (2022).","journal-title":"NPJ Genom. Med."},{"key":"58152_CR46","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1600-051X.1987.tb01510.x","volume":"14","author":"N Blomqvist","year":"1987","unstructured":"Blomqvist, N. On the bias caused by regression toward the mean in studying the relation between change and initial value. J. Clin. Periodontol. 14, 34\u201337 (1987).","journal-title":"J. Clin. Periodontol."},{"key":"58152_CR47","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/sim.2538","volume":"26","author":"Yu-Kang Tu","year":"2007","unstructured":"Tu, Yu-Kang & Gilthorpe, M. S. Revisiting the relation between change and initial value: a review and evaluation. Stat. Med. 26, 443\u2013457 (2007).","journal-title":"Stat. Med."},{"key":"58152_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jclinepi.2017.12.018","volume":"96","author":"B Speich","year":"2018","unstructured":"Speich, B. et al. Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data. J. Clin. Epidemiol. 96, 1\u201311 (2018).","journal-title":"J. Clin. Epidemiol."},{"key":"58152_CR49","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1016\/S0140-6736(14)61730-X","volume":"385","author":"JL Mega","year":"2015","unstructured":"Mega, J. L. et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 385, 2264\u20132271 (2015).","journal-title":"Lancet"},{"key":"58152_CR50","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1161\/CIRCULATIONAHA.116.024436","volume":"135","author":"P Natarajan","year":"2017","unstructured":"Natarajan, P. et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation 135, 2091\u20132101 (2017).","journal-title":"Circulation"},{"key":"58152_CR51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1176\/appi.ajp.2018.17121363","volume":"176","author":"Jian-Ping Zhang","year":"2019","unstructured":"Zhang, J. P. et al. Schizophrenia polygenic risk score as a predictor of antipsychotic efficacy in first-episode psychosis. Am. J. Psychiatry 176, 21\u201328 (2019).","journal-title":"Am. J. Psychiatry"},{"key":"58152_CR52","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.119.044434","volume":"141","author":"A Damask","year":"2020","unstructured":"Damask, A. et al. Patients with high genome-wide polygenic risk scores for coronary artery disease may receive greater clinical benefit from alirocumab treatment in the ODYSSEY OUTCOMES trial. Circulation 141, 624\u2013636 (2020).","journal-title":"Circulation"},{"key":"58152_CR53","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1161\/CIRCULATIONAHA.119.043805","volume":"141","author":"NA Marston","year":"2020","unstructured":"Marston, N. A. et al. Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score: results from the fourier trial. Circulation 141, 616\u2013623 (2020).","journal-title":"Circulation"},{"key":"58152_CR54","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2337\/db20-0530","volume":"70","author":"JH Li","year":"2021","unstructured":"Li, J. H. et al. A polygenic score for type 2 diabetes risk is associated with both the acute and sustained response to sulfonylureas. Diabetes 70, 293\u2013300 (2021).","journal-title":"Diabetes"},{"key":"58152_CR55","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1093\/eurjpc\/zwab192","volume":"29","author":"NM Tapela","year":"2022","unstructured":"Tapela, N. M. et al. Are polygenic risk scores for systolic blood pressure and ldl-cholesterol associated with treatment effectiveness, and clinical outcomes among those on treatment? Eur. J. Preventive Cardiol. 29, 925\u2013937 (2022).","journal-title":"Eur. J. Preventive Cardiol."},{"key":"58152_CR56","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41397-024-00333-2","volume":"24","author":"D T\u00fcrkmen","year":"2024","unstructured":"T\u00fcrkmen, D. et al. Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in ccb treatment compared to pharmacogenetic variants alone. Pharmacogenomics J. 24, 12 (2024).","journal-title":"Pharmacogenomics J."},{"key":"58152_CR57","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0895-7061(97)00495-0","volume":"11","author":"BJ Materson","year":"1998","unstructured":"Materson, B. J., Reda, D. J. & Williams, D. W. Comparison of effects of antihypertensive drugs on heart rate: changes from baseline by baseline group and over time. Am. J. Hypertension 11, 597\u2013601 (1998).","journal-title":"Am. J. Hypertension"},{"key":"58152_CR58","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s41588-021-00870-7","volume":"53","author":"J Mbatchou","year":"2021","unstructured":"Mbatchou, J. et al. Computationally efficient whole-genome regression for quantitative and binary traits. Nat. Genet. 53, 1097\u20131103 (2021).","journal-title":"Nat. Genet."},{"key":"58152_CR59","doi-asserted-by":"publisher","first-page":"s13742","DOI":"10.1186\/s13742-015-0047-8","volume":"4","author":"CC Chang","year":"2015","unstructured":"Chang, C. C. et al. Second-generation plink: rising to the challenge of larger and richer datasets. Gigascience 4, s13742\u2013015 (2015).","journal-title":"Gigascience"},{"key":"58152_CR60","doi-asserted-by":"publisher","unstructured":"Meyer, H. V. plinkQC: genotype quality control in genetic association studies. meyer-lab-cshl\/plinkQC. https:\/\/doi.org\/10.5281\/zenodo.3934294 (2022).","DOI":"10.5281\/zenodo.3934294"},{"key":"58152_CR61","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/nature14962","volume":"526","author":"UK10K.","year":"2015","unstructured":"UK10K. The UK10K project identifies rare variants in health and disease. Nature 526, 82 (2015).","journal-title":"Nature"},{"key":"58152_CR62","doi-asserted-by":"publisher","unstructured":"Krasheninina, O. et al. Open-source mapping and variant calling for large-scale ngs data from original base-quality scores. bioRxiv https:\/\/doi.org\/10.1101\/2020.12.15.356360 (2020).","DOI":"10.1101\/2020.12.15.356360"},{"key":"58152_CR63","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ajhg.2015.12.022","volume":"98","author":"KJ Galinsky","year":"2016","unstructured":"Galinsky, K. J. et al. Fast principal-component analysis reveals convergent evolution of adh1b in europe and east asia. Am. J. Hum. Genet. 98, 456\u2013472 (2016).","journal-title":"Am. J. Hum. Genet."},{"key":"58152_CR64","unstructured":"PGS Catalog Team. PGS Catalog Calculator v2.0. https:\/\/github.com\/PGScatalog\/pgsc_calc(2023)."},{"key":"58152_CR65","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41588-021-00783-5","volume":"53","author":"SA Lambert","year":"2021","unstructured":"Lambert, S. A. et al. The polygenic score catalog as an open database for reproducibility and systematic evaluation. Nat. Genet. 53, 420\u2013425 (2021).","journal-title":"Nat. Genet."},{"key":"58152_CR66","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ajhg.2021.11.008","volume":"109","author":"F Priv\u00e9","year":"2022","unstructured":"Priv\u00e9, F. et al. Portability of 245 polygenic scores when derived from the UK Biobank and applied to 9 ancestry groups from the same cohort. Am. J. Hum. Genet. 109, 12\u201323 (2022).","journal-title":"Am. J. Hum. Genet."},{"key":"58152_CR67","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1093\/bioinformatics\/btaa1029","volume":"36","author":"F Priv\u00e9","year":"2020","unstructured":"Priv\u00e9, F., Arbel, J. & Vilhj\u00e1lmsson, B. J. Ldpred2: better, faster, stronger. Bioinformatics 36, 5424\u20135431 (2020).","journal-title":"Bioinformatics"},{"key":"58152_CR68","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41562-019-0566-x","volume":"3","author":"AD Grotzinger","year":"2019","unstructured":"Grotzinger, A. D. et al. Genomic structural equation modelling provides insights into the multivariate genetic architecture of complex traits. Nat. Hum. Behav. 3, 513\u2013525 (2019).","journal-title":"Nat. Hum. Behav."},{"key":"58152_CR69","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41586-021-04064-3","volume":"600","author":"SE Graham","year":"2021","unstructured":"Graham, S. E. et al. The power of genetic diversity in genome-wide association studies of lipids. Nature 600, 675\u2013679 (2021).","journal-title":"Nature"},{"key":"58152_CR70","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/s41588-018-0205-x","volume":"50","author":"E Evangelou","year":"2018","unstructured":"Evangelou, E. et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat. Genet. 50, 1412\u20131425 (2018).","journal-title":"Nat. Genet."},{"key":"58152_CR71","doi-asserted-by":"publisher","unstructured":"Sadler, M. Leveraging large-scale biobank EHRs to enhance pharmacogenetics of cardiometabolic disease medications. masadler\/PGxEHR. https:\/\/doi.org\/10.5281\/zenodo.14026836 (2024).","DOI":"10.5281\/zenodo.14026836"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58152-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58152-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58152-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T12:45:42Z","timestamp":1743252342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58152-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["58152"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-58152-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.04.06.24305415","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"26 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MCS has been consulting for 5 Prime Sciences at the time of the submission; however, this study was performed separately with no relationship to 5 Prime Sciences. The results and opinions expressed in this paper do not represent those of 5 Prime Sciences. The other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2913"}}